Skip to main content

Advertisement

SpringerLink
Log in

The Systemic Absorption of Etoposide after Intravaginal Administration in Patients with Cervical Intraepithelial Lesions Associated with Human Papillomavirus Infection

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Purpose

The purpose of this study was to determine the systemic absorption and the release of etoposide in cervical tissue administered via a vaginal ovule to women diagnosed with cervical intraepithelial lesions associated with human papillomavirus (HPV).

Methods

Fifteen women with low- and high-grade intraepithelial neoplasia confirmed by colposcopic test received a 50-mg intravaginal etoposide dose three times a week for 3 weeks. At the end of the study period, paralleled with the last ovule administered, blood samples were collected over a period of 24 h, and in situ cervical samples were obtained at 3 and 10 h after drug administration. Etoposide concentrations were determined in plasma and in in situ cervical samples using the high-performance liquid chromatography method with electrochemical detection.

Results

Pharmacokinetic analyses of plasma data indicated low or lack of systemic exposure of etoposide after the vaginal administration. Nevertheless, high concentrations of etoposide were found in all in situ cervical samples, indicating that etoposide could be released from its pharmaceutical formulation.

Conclusions

The results of the study suggest that the etoposide administered as intravaginal ovule is safe and tolerable and apparently could be a suitable option in patients with cervical intraepithelial neoplasia. Clinical results and the true impact on HPV infection and evolution of dysplasia need to be confirmed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. F. X. Bosch (2003) ArticleTitleEpidemiology of human papillomavirus infections: new option for cervical cancer prevention Salud Publica Mex. 45 S326–S329 Occurrence Handle14746025

    PubMed  Google Scholar 

  2. A. T. Lorincz (2003) ArticleTitleScreening for cervical cancer: new alternatives and research Salud Publica Mex. 45 S376–S387 Occurrence Handle14746031

    PubMed  Google Scholar 

  3. M. Fukushima Y. Yamakawa S. Shimano M. Hashimoto Y. Sawada K. Fujinaga (1990) ArticleTitleThe physical state of human papillomavirus 16 DNA in cervical carcinoma and cervical intraepithelial neoplasia Cancer 66 2155–2161 Occurrence Handle1:CAS:528:DyaK3MXitVClu7Y%3D Occurrence Handle2171746

    CAS  PubMed  Google Scholar 

  4. A. Iwasawa P. Nieminen M. Lehtinen J. Paavoneen (1996) ArticleTitleHuman papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction Cancer 77 2275–2279 Occurrence Handle10.1002/(SICI)1097-0142(19960601)77:11<2275::AID-CNCR14>3.0.CO;2-U Occurrence Handle1:STN:280:DyaK283isVyqsQ%3D%3D Occurrence Handle8635095

    Article  CAS  PubMed  Google Scholar 

  5. H. Hausen (2000) ArticleTitlePapillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis J. Natl. Cancer Inst. 92 690–698 Occurrence Handle10.1093/jnci/92.9.690 Occurrence Handle10793105

    Article  PubMed  Google Scholar 

  6. H. Furumoto M. Irahara (2002) ArticleTitleHuman papilloma virus (HPV) and cervical cancer J. Med. Investig. 49 124–133

    Google Scholar 

  7. M. M. Holmes S. H. Weaver S. T. Vermillion (1999) ArticleTitleA randomized, double-blind, placebo-controlled trial of 5-fluoruracil for the treatment of cervicovaginal human papillomavirus Infect. Dis. Obstet. Gynecol. 7 186–189 Occurrence Handle10.1002/(SICI)1098-0997(1999)7:4<186::AID-IDOG4>3.0.CO;2-Z Occurrence Handle1:STN:280:DyaK1Mzns1GjtA%3D%3D Occurrence Handle10449266

    Article  CAS  PubMed  Google Scholar 

  8. Y. Liu A. McKalip B. Herman (2000) ArticleTitleHuman papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: roles of p53 and caspase activation J. Cell. Biochem. 78 334–349 Occurrence Handle1:CAS:528:DC%2BD3cXkt1aqtLw%3D Occurrence Handle10842327

    CAS  PubMed  Google Scholar 

  9. G. L. Chen L. Yang T. C. Rowe B. D. Halligan K. M. Tewey L. F. Liu (1984) ArticleTitleNonintercalitive antitumor drugs interfere with the breakage reunion reaction of mammalian DNA topoisomerase II J. Biol. Chem. 259 13560–13566 Occurrence Handle1:CAS:528:DyaL2MXhslahtw%3D%3D Occurrence Handle6092381

    CAS  PubMed  Google Scholar 

  10. M. Sioud P. Forterre A. M. Recondo Particlede (1987) ArticleTitleEffects of the antitumor drug VP16 (etoposide) on the archaebacterial. Halobacterium GRB1.7 Kb plasmid in vivo Nucleic Acids Res. 15 8217–8234 Occurrence Handle1:CAS:528:DyaL1cXht1yn Occurrence Handle3671082

    CAS  PubMed  Google Scholar 

  11. J. M. Henwood R. N. Brogden (1990) ArticleTitleEtoposide: a review of itspharmacodynamic and pharmacokinetics properties and therapeutic potential in combination chemotherapy of cancer Drugs 39 438–490 Occurrence Handle1:STN:280:DyaK3c3ivVWquw%3D%3D Occurrence Handle2184009 Occurrence Handle10.2165/00003495-199039030-00008

    Article  CAS  PubMed  Google Scholar 

  12. D. Busse G. Wurthwein C. Hinske G. Hempel M. F. Fromm M. Eichelbaum H. K. Kroemer F. W. Busch (2002) ArticleTitlePharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration Naunyn-Schmiedebergs Arch. Pharmacol. 366 218–225 Occurrence Handle1:CAS:528:DC%2BD38XlvVCjs70%3D Occurrence Handle12172704

    CAS  PubMed  Google Scholar 

  13. A. Ballestrero A. Rubagotti P. Stura F. Ferrando D. Amoroso M. Rinaldini P. Sismondi F. Genta M. Mesiti F. Brema F. Patrone F. Boccardo InstitutionalAuthorNameGROETA (Italian Breast Cancer Adjuvant study) (2001) ArticleTitleAdjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5 year results of a pilot trial Oncology 60 221–227 Occurrence Handle10.1159/000055322 Occurrence Handle1:CAS:528:DC%2BD3MXjvVWqtLw%3D Occurrence Handle11340373

    Article  CAS  PubMed  Google Scholar 

  14. H. Kobayashi Y. Kawashima (1989) ArticleTitleA case of recurrent uterine cervical cancer successfully treated with etoposide Gan To Kagaku Ryoho 16 3279–3282 Occurrence Handle1:STN:280:DyaL1MzptFGnug%3D%3D Occurrence Handle2782919

    CAS  PubMed  Google Scholar 

  15. M. Ikeda K. Noda M. Hiura T. Tamaya M. Ozaki M. Hatae M. Ozawa T. Yamabe K. Tanaka R. Izumi H. Okada Y. Ogita H. Hoshiai (1998) ArticleTitleLate phase II trial oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group-Cervical Cancer Group Gan To Kagaku Ryoho 25 2249–2257 Occurrence Handle1:STN:280:DyaK1M%2FpslOmtQ%3D%3D Occurrence Handle9881082

    CAS  PubMed  Google Scholar 

  16. K. Noda K. Tanaka M. Ozaki K. Hirabayasi K. Hasegawa I. Nishiya M. Yakushiji R. Izumi Y. Tomoda Y. Ogita H. Sugimori T. Yamabe R. Kudo A. Yajima Y. Terashima S. Fujii Y. Suzuoki H. Okada I. Kono K. Ochiai T. Yamamoto M. Ikeda M. Umesaki T. Saito H. Niitani (1998) ArticleTitleEarly phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group-Cervical-Ovarian Cancer Group Gan To Kagaku Ryoho 25 2061–2068 Occurrence Handle1:STN:280:DyaK1M%2Fls1artQ%3D%3D Occurrence Handle9838908

    CAS  PubMed  Google Scholar 

  17. P. G. Rose J. A. Blessing L. Van S. Waggonner (1998) ArticleTitleProlonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study Gynecol. Oncol. 70 263–266 Occurrence Handle1:CAS:528:DyaK1cXmsVClt7w%3D Occurrence Handle9740702

    CAS  PubMed  Google Scholar 

  18. F. L. Meyskens E. Surwit T. E. Moon J. M. Childers J. R. Davis R. T. Dorr C. S. Johnson D. S. Alberto (1994) ArticleTitleEnhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial J. Natl. Cancer Inst. 86 539–543 Occurrence Handle8133537

    PubMed  Google Scholar 

  19. M. Maiman D. H. Watts J. Anderson P. Clax M. Merino M. A. Kendall (1999) ArticleTitleVaginal 5-fluoruracil for high-grade cervical dysplasia in human immunodeficiency virus infection; a randomized trial Obstet. Gynecol. 94 954–961 Occurrence Handle10.1016/S0029-7844(99)00407-X Occurrence Handle1:CAS:528:DyaK1MXntlensbg%3D Occurrence Handle10576182

    Article  CAS  PubMed  Google Scholar 

  20. M. M. Alper B. N. Barwin W. M. McLean I. J. McGilveray S. Sved (1985) ArticleTitleSystemic absorption of metronidazole by the vaginal route Obstet. Gynecol. 65 781–784 Occurrence Handle1:STN:280:DyaL2M3hsVOlsQ%3D%3D Occurrence Handle4000568

    CAS  PubMed  Google Scholar 

  21. C. Hoffman N. Focke G. Franke M. Zschiesche W. Siegmund (1995) ArticleTitleComparative bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration Int. J. Clin. Pharmacol. Ther. 33 232–239

    Google Scholar 

  22. J. Pérez-Urizar Y. F. Picazo B. Navarro-González F. J. Flores-Murrieta G. Castañeda-Hernández (1996) ArticleTitleA new rapid and economic high performance liquid chromatographic assay with electrochemical detection for determination of etoposide (VP16) in human plasma samples J. Liq. Chromatogr. Relat. Technol. 19 939

    Google Scholar 

  23. Estadísticas de Mortalidad en México: muertes registradas en el año 2002. Salud Publica Mex. 46:169–185 (2004).

  24. K. Bodner B. Bodner-Adler F. Wierrani O. Kimberger C. Denk W. Grunberger (2002) ArticleTitleIs therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis Anticancer Res. 22 3733–3736 Occurrence Handle12552985

    PubMed  Google Scholar 

  25. K. Nakayama Y. Sano Y. Endo H. Sato T. Ohyama M. Yamaguchi (1992) ArticleTitleClinical studies on intravaginal administration of CDDP for dysplasia, carcinoma in situ and microinvasive carcinoma of the uterine cervix Nippon Sanka Fujinka Gakkai Zasshi 44 208–214 Occurrence Handle1:STN:280:DyaK387osFehtw%3D%3D Occurrence Handle1545173

    CAS  PubMed  Google Scholar 

  26. J. L. Gonzalez-Sanchez G. Flores-Murrieta J. Chavez-Brambilia J. M. Deolarte-Manzano A. F. Andrade-Manzano (2002) ArticleTitleTopical 5-Fluoruracil for treatment of vaginal intraepithelial neoplasms Ginecol. Obstet. Mex. 70 244–247 Occurrence Handle12148464

    PubMed  Google Scholar 

  27. M. L. Slevin P. I. Clark S. P. Joel S. Malik R. J. Osborne W. M. Gregory D. G. Lowe R. H. Reznek P. F. Wrigley (1989) ArticleTitleA randomised trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer J. Clin. Oncol. 7 1333–1340 Occurrence Handle1:STN:280:DyaL1MzmtFGluw%3D%3D Occurrence Handle2549204

    CAS  PubMed  Google Scholar 

  28. P. I. Clark M. L. Slevin S. P. Joel R. J. Osborne D. I. Talbot P. W. Johnson R. Reznek T. Masud W. Gregory P. F. Wrigley (1994) ArticleTitleA randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity J. Clin. Oncol. 12 1427–1435 Occurrence Handle1:STN:280:DyaK2c3ptlSksw%3D%3D Occurrence Handle8021734

    CAS  PubMed  Google Scholar 

  29. P. I. Clark S. P. Joel M. L. Slevin (1989) ArticleTitleA pharmacokinetics hypothesis for the clinical efficacy of etoposide in small-cell lung cancer Proc. ASCO 8 66

    Google Scholar 

  30. J. D. Jonkman-de Vries H. Rosing O. Tellingen Particlevan C. Neef A. C. Dubbelman A. Bult W. W. Bokkel-Huinink Particleten B. G. Taal J. H. Beijnen (1995) ArticleTitlePharmacokinetics of etoposide after oral and intravenous administration in patients with gastric carcinoma Clin. Drug Investig. 10 86

    Google Scholar 

  31. J. L. Aguilar-Ponce Y. Flores-Picazo J. Pérez-Urizar G. Castañeda-Hernández J. W. Zinser-Sierra A. Dueñas-Gonzalez E. Calderon-Flores B. A. Segura-Pacheco J. Garza-Salazar Particlede la (1999) ArticleTitleBioavailability of etoposide after oral administration of the solution marketed for intravenous use: therapeutic and pharmaeconomic perspectives Arch. Med. Res. 30 212–215 Occurrence Handle1:STN:280:DyaK1Mzls1ykuw%3D%3D Occurrence Handle10427872

    CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by the Research Medical Division of Laboratorios Lemery S.A. de C.V. (México City).

Author information

Authors and Affiliations

  1. División de Investigación Básica, Instituto Nacional de Cancerología (INCan), Av. San Fernando # 22 Tlalpan, 14000, México, D.F., México

    P. García-López, E. Cervera, A. I. Hernández-Pájaro, A. Mohar-Betancourt & A. Meneses

  2. Laboratorios Lemery S.A. de C.V., México D.F., México

    M. Coll, L. Reyes-Vermot, M. A. Torres & G. Ábrego-Pérez

  3. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, México D.F., México

    G. Castañeda-Hernandez

  4. Instituto de Investigaciones Biomédicas, UNAM, México D.F., México

    A. Mohar-Betancourt

Authors
  1. P. García-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Coll
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Cervera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Reyes-Vermot
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. A. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Ábrego-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. I. Hernández-Pájaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Castañeda-Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Mohar-Betancourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Meneses
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. García-López.

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-López, P., Coll, M., Cervera, E. et al. The Systemic Absorption of Etoposide after Intravaginal Administration in Patients with Cervical Intraepithelial Lesions Associated with Human Papillomavirus Infection. Pharm Res 23, 378–383 (2006). https://doi.org/10.1007/s11095-005-9142-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-005-9142-3

Key Words

Search

Navigation